Sleep Apnea Clinical Trial
— CAT-PEFOfficial title:
Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study
Verified date | April 2021 |
Source | ResMed |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is designed to demonstrate feasibility of study conduct and that acceptable adherence to adaptive servo-ventilation (ASV) therapy can be achieved in recently hospitalized HFpEF patients with moderate to severe sleep apnea. All subjects meeting the criteria will receive ASV therapy.
Status | Terminated |
Enrollment | 6 |
Est. completion date | November 15, 2017 |
Est. primary completion date | November 15, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients 18 years or older 2. Patients with heart failure with preserved ejection fraction (HFpEF; LVEF =50%) 3. Hospital admission or equivalent (such as ER visit alone or clinic visit alone) and acute decompensated HF as determined by: 1. Dyspnea at rest or with minimal exertion AND 2. Treatment with at least one dose of IV diuretic or ultrafiltration AND 3. At least two of the following signs and symptoms: i. Orthopnea ii. Pulmonary rales that do not clear with cough iii. Congestion on chest X-ray iv. Local BNP or NT pro-BNP level: A. No current atrial fibrillation (AFib): BNP=100 pg/mL or NT pro- BNP=300 pg/mL OR B. Current AFib: BNP=150 pg/mL or NT pro-BNP=450 pg/mL 4. Sleep disordered breathing (SDB) documented by screening polygraphy with an AHI=15 events/hour (e/hr) 5. Patient is able to fully understand study information and sign informed consent Exclusion Criteria: 1. Right-sided heart failure without left-sided failure 2. Current chronic use (within 4 weeks of study entry) of any PAP therapy (eg, CPAP, APAP, or bi-level) or contraindicated for PAP therapy 3. Sustained systolic blood pressure <80 mmHg at baseline 4. Complex congenital heart disease 5. Constrictive pericarditis 6. Chronic hypoxemia as evidenced by sustained oxygen saturation = 85% at rest during the day or at start of nocturnal oximetry recording or regular use of oxygen therapy (day or night) 7. Transient ischemic attack (TIA) or Stroke within 3 months prior to study entry 8. Definite clinically evident acute myocardial infarction within 3 months of study entry 9. Known amyloidosis, hypertrophic obstructive cardiomyopathy, or arteriovenous fistulas 10. Moderate or greater valvular heart disease as the primary reason for heart failure 11. Pregnant, or planning to become pregnant during the study period 12. In the opinion of the investigator, the index acute decompensated HF event was due primarily to uncontrolled AFib with fast ventricular response rate 13. Inability to comply with planned study procedures |
Country | Name | City | State |
---|---|---|---|
Germany | Heart and Diabetes Center - West Rhine-Westphalia | Bad Oeynhausen | |
United States | Inova Heart and Vascular Institute | Falls Church | Virginia |
United States | Thomas Jefferson University | Philadelphia | Pennsylvania |
United States | University of California San Diego | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
ResMed |
United States, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ASV Adherence | Average hours used per day | 3 months | |
Secondary | KCCQ-12 | Change in KCCQ-12 score. Cardiomyopathy Questionnaire (Kansas City) (KCCQ-12) is a short questionnaire to evaluate quality of life in heart failure patients. All scores are scaled from 0-100 where low scares represent very poor health and high scores represent excellent health. | 3 months | |
Secondary | Hospitalizations | Number of hospitalizations per subject | 3 months | |
Secondary | Death | Number of deaths | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05582070 -
Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction
|
N/A | |
Recruiting |
NCT03919955 -
A Novel Pharmacological Therapy for Obstructive Sleep Apnea
|
Phase 2 | |
Completed |
NCT03927547 -
Sleep Disordered Breathing and Cardiopulmonary Disease in Peruvian Highlanders
|
N/A | |
Recruiting |
NCT04007380 -
Psychosocial, Cognitive, and Behavioral Consequences of Sleep-disordered Breathing After SCI
|
N/A | |
Completed |
NCT02188498 -
Electrocardiography Data Analysis in Sleep Disorders
|
||
Completed |
NCT01503164 -
Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism
|
N/A | |
Recruiting |
NCT00747890 -
Surgical Treatment of Mild Obstructive Sleep Apnea
|
N/A | |
Active, not recruiting |
NCT00738179 -
Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease
|
Phase 3 | |
Completed |
NCT00841906 -
Alice PDx User/Validation Extended Trial
|
N/A | |
Completed |
NCT00202501 -
Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome
|
N/A | |
Completed |
NCT00047463 -
Effects of Treating Obstructive Sleep Apnea in Epilepsy
|
Phase 2 | |
Not yet recruiting |
NCT06029881 -
Portable System for Non-intrusive Monitoring of Sleep
|
||
Recruiting |
NCT06093347 -
Central Apnoea Monitor Study
|
||
Terminated |
NCT05445869 -
Severe OSA Study (SOS)
|
N/A | |
Withdrawn |
NCT04096261 -
The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease
|
||
Recruiting |
NCT04575740 -
Phenotyping Mechanistic Pathways for Adverse Health Outcomes in Sleep Apnea
|
N/A | |
Completed |
NCT04676191 -
Validation of a Contactless Vital Signs Measurement Sensor
|
N/A | |
Recruiting |
NCT06015620 -
Comorbidities Resolution After MGB Surgery and Change in Body Composition
|
||
Completed |
NCT06051097 -
Metabolic Syndrome and Obstructive Sleep Apnea
|
||
Completed |
NCT05687097 -
Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury
|